z-logo
open-access-imgOpen Access
Platelet-Rich plasma injections treatment in patients having early osteoarthritis of knee joint.
Author(s) -
Imran Ali,
Qazi Masroor Ali,
Syed Hashim Raza
Publication year - 2021
Publication title -
the professional medical journal/the professional medical journal
Language(s) - English
Resource type - Journals
eISSN - 2071-7733
pISSN - 1024-8919
DOI - 10.29309/tpmj/2021.28.08.6060
Subject(s) - medicine , womac , osteoarthritis , platelet rich plasma , arthritis , prospective cohort study , significant difference , physical therapy , surgery , platelet , alternative medicine , pathology
Objective: To find out the outcome following intra-articular platelet-rich plasma (PRP) injection in patients having early OA of knee. Study Design: Prospective Study. Setting: Tahira Jamshed Medical Complex, Bahawalpur. Period: January 2019 to February 2020. Material & Methods: A total of 112 cases of both gender, aged 40 to 60 years, Grade I and Grade II OA, having symptoms of OA for a minimum duration of 1 year, were enrolled. All participants were assessed for physical activity and pain linked with arthritis as per “Western Ontario and McMaster University Arthritis Index (WOMAC) score”. Results: Out of a total 98 cases who completed the study, majority 58 (59.2%) were female, 67 (68.4%) had Kellgren-Lawrence Grade-I OA and 81 (82.7%) were experiencing OA symptoms with a duration of less than 2 years. The difference between mean WOMAC score before the treatment (80.38+6.3) and after PRP treatment (42.93+6.9) turned out to be statistically significant (p value < 0.001). After the treatment, cases having duration of symptoms of OA as less than 2 years had significantly less WOMAC score (p value = 0.0418). Conclusion: PRP treatment in patients having early OA seemed to be quite efficacious. The effects of PRP injections were more favorable in cases having clinical symptoms of OA for less than 2 years of duration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here